文献速递淋巴瘤

经典霍奇金淋巴瘤的初始治疗与相对生存:1989-2017年荷兰全国人群研究

Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989-2017.
PubMed 文献 · Leukemia · 2020-05-28

该全国人群研究纳入9985例经典霍奇金淋巴瘤患者,评估1989-2017年初始治疗与相对生存趋势。2000年起18-69岁I/II期患者几乎不再单用放疗,III/IV期以化疗为主,各期≥70岁患者约20%未接受抗肿瘤治疗。5年相对生存改善主要限于18-59岁患者,≥60岁患者未见显著获益。

要点

  • 2000年起18-69岁I/II期患者几乎不再单用放疗,III/IV期以化疗为主。
  • 整个研究期间各期≥70岁患者约20%未接受抗肿瘤治疗。
  • 2010-2017年诊断的I/II期患者5年相对生存随年龄增高而下降,≥70岁为61%。

核心结论

  • 生存改善可能与经典霍奇金淋巴瘤管理进步有关,但这些成就似乎未转化为≥60岁患者的显著获益,老年患者亟需新疗法以降低超额死亡。

研究设计与样本

  • 荷兰全国人群研究,纳入9985例经典霍奇金淋巴瘤患者,评估1989-2017年初始治疗与相对生存趋势。

主要发现

  • 2000年起18-69岁I/II期患者几乎不再单用放疗,化疗联合放疗应用更广泛。
  • III/IV期患者首选单纯化疗。
  • 整个研究期间各期≥70岁患者约20%未接受抗肿瘤治疗。
  • 5年相对生存的最大改善限于18-59岁患者。
  • 2010-2017年诊断的I/II期患者5年相对生存:18-29岁99%、30-39岁98%、40-49岁100%、50-59岁93%、60-69岁84%、≥70岁61%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Population-based studies of classical Hodgkin lymphoma (cHL) in contemporary clinical practice are scarce. The aim of this nationwide population-based study is to assess trends in primary therapy and relative survival (RS) during 1989-2017. We included 9,985 patients with cHL. Radiotherapy alone was virtually not applied as from 2000 among patients aged 18-69 years with stage I/II disease, following the broader application of chemotherapy combined with radiotherapy. Chemotherapy only was the preferred treatment for patients with stage III/IV disease. Throughout the entire study period, around 20% of patients aged ≥70 years across all disease stages received no anti-neoplastic therapy. The most considerable improvements in 5-year RS were confined to patients aged 18-59 years. Five-year RS for patients with stage I/II disease diagnosed during 2010-2017 was 99%, 98%, 100%, 93%, 84%, and 61% for patients aged 18-29, 30-39, 40-49, 50-59, 60-69, and ≥70 years, respectively. The corresponding estimates for stage III/IV disease were 96%, 92%, 90%, 80%, 58%, and 46%. Collectively, the improvements in survival likely relate to advances in cHL management. These achievements, however, do not seem to translate into significant benefits for patients ≥60 years. Therefore, novel therapies are urgently needed to reduce excess mortality in elderly cHL patients.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Driessen J, Visser O, Zijlstra JM, et al. Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989-2017. Leukemia. 2020. PMID: 32461630. doi:10.1038/s41375-020-0875-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。